|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0038952,
umls-concept:C0205179,
umls-concept:C0220825,
umls-concept:C0243161,
umls-concept:C0280100,
umls-concept:C0282461,
umls-concept:C0332197,
umls-concept:C0332293,
umls-concept:C0449258,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C0879615,
umls-concept:C0939537,
umls-concept:C1516048,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
24
|
|
pubmed:dateCreated |
2009-8-19
|
|
pubmed:abstractText |
From February 2001 to February 2002, 946 patients with advanced GI stromal tumors (GISTs) treated with imatinib were included in a controlled EORTC/ISG/AGITG (European Organisation for Research and Treatment of Cancer/Italian Sarcoma Group/Australasian Gastro-Intestinal Trials Group) trial. This analysis investigates whether the response classification assessed by RECIST (Response Evaluation Criteria in Solid Tumors), predicts for time to progression (TTP) and overall survival (OS).
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-10458228,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-10655437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-10894866,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-11287975,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-11705489,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-11872347,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-12181401,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-12239065,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-12504660,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-12528774,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-12957455,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-14734662,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-15001674,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-15100500,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-15451219,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-15547201,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-15659504,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-15797301,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-15919202,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-16098458,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-16616487,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-17046465,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-17056915,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-17369574,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-17470865,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-17470866,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-17586092,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-17845846,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-18235121,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-18235122,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-18376462,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-18650514,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19620483-9438854
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BlayJean-YvesJY,
pubmed-author:BuiBinhB,
pubmed-author:CasaliPaolo GPG,
pubmed-author:FindlayMichaelM,
pubmed-author:HogendoornPancras C WPC,
pubmed-author:IsselsRolfR,
pubmed-author:JudsonIanI,
pubmed-author:Le CesneAxelA,
pubmed-author:LeyvrazSergeS,
pubmed-author:ReichardtPeterP,
pubmed-author:SchoffskiPatrickP,
pubmed-author:SciotRafR,
pubmed-author:Van GlabbekeMartineM,
pubmed-author:VerweijJaapJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3969-74
|
|
pubmed:dateRevised |
2010-9-27
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
|
|
pubmed:affiliation |
Department of Medicine, Institut Gustave Roussy, Villejuif, France. lecesne@igr.fr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|
